A non-invasive diagnostic indicator for Hepatocellular carcinoma
Research type
Research Study
Full title
The role of urinary volatile organic compounds as a non-invasive diagnostic biomarker for hepatocellular carcinoma
IRAS ID
173809
Contact name
Chris Probert
Contact email
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Thousands of organic compounds are found in gaseous form in human faecal and urinary samples. These are derived as byproducts of a combination of human and intestinal bacteria metabolism. Previous work has identified unique compounds in urine related to different underlying diseases. This includes urological and non-urological cancers.
We hypothesis that there will be a unique compound profile in the urine of patients who have underlying hepatocellular carcinoma (HCC). This will potentially lead to a new diagnostic/screening tool for HCC.
We propose to collect urine samples from patients attending planned outpatient clinic appointments. These patients will have either chronic liver disease with and with out cirrhosis, or underlying HCC. Those with HCC will have not recived previous treatment for their HCC. The patients must have a formal diagnosis for their liver disease inorder to be included. Gaseous compounds will be extracted from these samples and analysed for patterns. Comparisons between the study groups will then be made, to look for a potential biomarker of HCC.REC name
London - Brighton & Sussex Research Ethics Committee
REC reference
15/LO/0836
Date of REC Opinion
11 May 2015
REC opinion
Further Information Favourable Opinion